18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...
23:04 , May 9, 2018 |  BC Extra  |  Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Aethlon Medical preclinical data

In vitro, the Aethlon Hemopurifier led to 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika virus from human blood serum in 5 hours. The...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Aethlon Hemopurifier regulatory update

Aethlon said it submitted a Humanitarian Use Device (HUD) application to FDA for Aethlon Hemopurifier to treat Ebola virus infection. The product is an extracorporeal device that selectively absorbs viruses and immunosuppressive toxins from blood....
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Hemopurifier: Clinical trial started

Aethlon began an open-label, U.S. clinical trial to evaluate Hemopurifier in about 10 HCV-infected patients with end-stage renal disease (ESRD) receiving chronic dialysis. Aethlon Medical Inc. (OTCQB:AEMD), San Diego, Calif.   Product: Hemopurifier   Business: Infectious...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Hemopurifier infectious data

Data from 10 evaluable patients with HCV infection in the Indian Extract-1 trial showed that treatment with Hemopurifier therapy during the first 3 days of a 48-week treatment regimen with SOC (peginterferon and ribavirin) led...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Hemopurifier regulatory update

Aethlon said it received updated guidance from FDA that the company can provide Hemopurifier to treat Ebola infection in the U.S. through expanded access “emergency use” provisions, which is an expansion of the previous guidance...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Hemopurifier regulatory update

Aethlon will provide its Hemopurifier under a compassionate use program in the U.S. to treat Ebola infection. Aethlon plans to start a U.S. feasibility study this month to evaluate the device for chronic viral pathogens,...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

Hemopurifier: Clinical trial start

Next month, Aethlon said it will begin a U.S. feasibility study to evaluate its Hemopurifier for chronic viral pathogens, such as HIV and HCV infection, and pandemic threats, including Ebola. The company also announced a...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

Hemopurifier: Additional data

Preliminary data from the first 9 patients with HCV genotype 1 infection in the Indian Extract-1 study showed that treatment with Hemopurifier therapy during the first 3 days of SOC (peginterferon and ribavirin) led to...